Quantum Surgical obtained market authorization from Taiwan

Quantum Surgical has obtained market authorization from the Taiwan Ministry of Health and Welfare for the use and commercialization of its Epione robotic platform in Taiwan. The platform enables early and minimally invasive treatment of tumors. Nearly 140,000 new cancer cases are diagnosed in Taiwan each year. Epione assists physicians in performing percutaneous tumor ablations where one or more needles are inserted through the skin to destroy the tumor. It allows physicians to treat inoperable tumors that are particularly difficult to reach due to their size or location at an early stage in a simple and effective way. The platform can be used to treat tumors and lesions in abdominal structures including the liver, kidneys and pancreas as well as chest and musculoskeletal structures. Over 1,400 patients have already been treated in Europe and the United States. The Epione device is CE marked for abdomen, chest and musculoskeletal structures indications and FDA cleared for abdominal ablation indication. Bertin Nahum, president and co-founder of Quantum Surgical, said thanks to the Taiwan Ministry of Health and Welfare market authorization the company is very excited to be able to offer its Epione solution to interventional oncologists in Taiwan. This is an important step that will provide Taiwanese patients with an innovative and minimally invasive treatment to treat their tumors at an early stage while improving their comfort. Laetitia Messner, vice president of clinical development of Quantum Surgical, said the Taiwan Ministry of Health and Welfare market authorization confirms the effectiveness of Epione and above all the relevance of its deployment in the territory where nearly 140,000 new cases of cancer are diagnosed each year.